Preparative and Process Chromatography Market Size to Reach USD 29.53 Billion by 2035 | SNS Insider

The U.S. preparative and process chromatography market is projected to reach $7.28B by 2035, while Europe is expected to reach $7.97B. Growth is attributed to expanding biologics manufacturing, GMP bioprocessing demand, and broader adoption of chromatography technologies. Overall, this is a positive outlook but likely limited to incremental industry/sector impact rather than near-term price moves.

Analysis

The investable read-through is not a broad ‘biotech up’ signal; it is a downstream-bioprocessing monetization story. The companies with the best economics are the ones that turn chromatography demand into recurring consumables and service revenue rather than one-time instrument placements, so DHR, TMO, and to a lesser extent RGEN/AVTR look better positioned than vendors dependent on lab capex cycles. Second-order benefit also accrues to CDMOs and biologics manufacturers with high purification complexity, because higher chromatography intensity usually tracks with more complex molecules and fewer generic alternatives.

The near-term risk is that this is a long-dated TAM call with little direct EPS impact over the next 1-3 quarters. If biotech funding stays tight, customers can defer new systems while still consuming existing resins/columns, which creates a split tape: consumables hold up, equipment growth disappoints. That means the market may overpay for ‘bioprocessing growth’ if it assumes linear conversion from market-size projections to revenue acceleration; the real catalyst path is backlog, utilization, and replenishment demand, not the forecast itself.

Contrarian view: the opportunity may already be partially embedded in premium multiples for the best tool names, while smaller pure-plays remain more execution-sensitive than the market implies. I would favor a relative-value expression over an outright thematic long: long diversified bioprocessing exposure, short a more instrument-heavy name if order growth slows. The thesis breaks if 2025-26 biologics capex reaccelerates, FDA approval cadence lifts new process builds, or pricing pressure from lower-cost Asian suppliers forces a margin reset.

Key Decisions for Investors

• Favor a basket long in DHR and TMO over the next 1-3 quarters: these names have the best mix of installed-base pull-through and services leverage; upside is steadier margin expansion rather than explosive top-line growth.
• Watch/accumulate RGEN on weakness only if bioprocessing order growth re-accelerates: higher beta to consumables demand, but the trade works only if customers resume capacity expansion rather than just replenishment.
• Use a relative-value pair: long DHR / short WAT over 3-6 months if the market starts differentiating consumables vs instrument capex; reward is multiple outperformance if chromatography spend remains recurring, risk is WAT benefiting from renewed analytical demand.
• Do not force an outright thematic long today; treat this as a confirmation signal and wait for next quarter’s backlog and organic growth prints before adding risk.
• Falsifier/watch item: if bioprocessing capex guides down for two consecutive quarters or pricing pressure shows up in gross margin, de-risk the entire basket.